RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Nanjing Frontier Biotechnologies acquired global rights to a novel broad-spectrum HIV neutralizing antibody from The Rockefeller University of the US. Frontier will combine the antibody with albuvirtide, its own long-acting anti-HIV/AIDS peptide, to treat and prevent HIV infection and AIDS. In 2016, Nanjing filed an NDA for albuvirtide with the CFDA, the world’s first NDA for a long-acting HIV medicine. Financial details of the agreement between Frontier and Rockefeller University were not disclosed.
Source: ChinaBio Today